Oncodesign is an international leader in the preclinical evaluation of anticancer therapies and stands out in the industry on the following points :
Innovation: Oncodesign devises new solutions (Pharmimage®, CReMEC, IMAkinib®, Nanocyclix®, etc.) that bring relevant rational, economic and competitive answers to therapeutic and biomarker development.
Science: Oncodesign boasts extensive know-how, rigor, and rationality, as exemplified through our synopses (custom-tailored drug program designs).
Technology: With its experimental models and state-of-the-art imaging for diagnostics, drug evaluation and monitoring, Oncodesign enjoys strong recognition as a technology company with unique integrated platforms.
Dynamism: Oncodesign's dynamic team stands out for its vitality, solidarity and capacity to develop solutions that anticipate customers' needs in order to offer rapid and effective responses.
Oncodesign holds a unique place in the industry and enjoys a strong image of quality.